Live Breaking News & Updates on Treat Various Tumor

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody . ....

Foster City , United States , Israel General , San Francisco , Tel Aviv , Flavius Martin , Compugen Ltd , Gilead Public Affairs , Securities Exchange , Gilead Sciences Inc , Tel Aviv Stock Exchange , Exchange Commission , Rights To Later Stage Development , Terms Of The Partnership , Gilead Sciences , Gilead Will Have Exclusive Rights , Later Stage Development , Protein Antibodies , Treat Various Tumor , Upfront Payment , Near Term Milestone Payment , Total Deal Value , Executive Vice President , Anat Cohen Dayag , Securities Act , Securities Exchange Act ,